Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK.

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK Keywords: myeloproliferative disorder; thrombosis (venous); direct oral anticoagulant therapy EN myeloproliferative disorder thrombosis (venous) direct oral anticoagulant therapy e79 e81 3 04/30/20 20200501 NES 200501 Myeloproliferative neoplasms (MPN) are associated with an increased rate of venous thromboembolism (VTE), which is a major cause of morbidity and mortality, especially in the more indolent diseases of polycythaemia rubra vera (PV) and essential thrombocythaemia (ET) (Pearson, [7]; Tefferi & Barbui, [9]). Six patients presented with two thrombotic events B . b The median follow-up period was 2-1 years (range, 0-1-7-8) with 18 patients initiated on DOACs (13 rivaroxaban 20 mg daily and 5 apixaban - 5 mg bd in four patients and 10 mg bd in one patient) and 14 patients changed from VKA or low molecular weight heparin (4 rivaroxaban, 9 apixaban and 1 edoxaban). [Extracted from the article]